share_log

Goldman Sachs Initiates Coverage On Immunovant With Buy Rating, Announces Price Target of $50

Goldman Sachs Initiates Coverage On Immunovant With Buy Rating, Announces Price Target of $50

高盛以买入评级启动对Immunovant的报道,宣布目标股价为50美元
Moomoo 24/7 ·  03/13 08:38

Goldman Sachs analyst Corinne Johnson initiates coverage on Immunovant (NASDAQ:IMVT) with a Buy rating and announces Price Target of $50.

高盛分析师科琳娜·约翰逊开始对Immunovant(纳斯达克股票代码:IMVT)进行报道,评级为买入,并宣布目标股价为50美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发